Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Affimed NV's enterprise value is $-13.72 Mil.
Affimed NV's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-71.10 Mil. Therefore, Affimed NV's EV-to-EBITDA for today is 0.19.
The historical rank and industry rank for Affimed NV's EV-to-EBITDA or its related term are showing as below:
AFMDQ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.19
Current: 0.19
During the past 12 years, the highest EV-to-EBITDA of Affimed NV was 0.19. The lowest was 0.00. And the median was 0.00.
AFMDQ's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 11.46
vs AFMDQ: 0.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Affimed NV's share price for today is $0.0001.
Affimed NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.982.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Affimed NV's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFMDQ vs SYRS, BTAX, TRVN: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Affimed NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Affimed NV EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Affimed NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Affimed NV's EV-to-EBITDA falls into.
Affimed NV's current Enterprise Value is $-13.72 Mil.
Affimed NV's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-71.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Affimed NV (AFMDQ) has a EV-to-EBITDA of 0.19 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Affimed NV.
Is Affimed NV's EV-to-EBITDA too high?
Affimed NV's current EV-to-EBITDA is 0.19. The Biotechnology industry median EV-to-EBITDA is 11.46. Affimed NV's value of 0.19 is 98.3% below this industry median. Overall, Affimed NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Affimed NV's EV-to-EBITDA compare to SYRS and BTAX?
Affimed NV's EV-to-EBITDA of 0.19 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 11.46. Affimed NV's value of 0.19 is 98.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.46, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Affimed NV's current EV-to-EBITDA of 0.19 is 98.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Affimed NV. For the Biotechnology industry, the median EV-to-EBITDA is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Affimed NV's current EV-to-EBITDA is 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Affimed NV stock overvalued right now?
Affimed NV (AFMDQ) has a current EV-to-EBITDA of 0.19. The current EV-to-EBITDA is 0.19 and 98.3% below the Biotechnology industry median of 11.46. Affimed NV's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Affimed NV (AFMDQ), the current EV-to-EBITDA is 0.19 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
16GF Score
Get the complete analysis for AFMDQ
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AFMDQ has been successfully added to your 
